Shanghai Yidi Biotechnology Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to an androgen receptor targeting moiety via a linker reported ...

Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to an androgen receptor targeting moiety through a linker acting as androgen ...

For years, scientists have focused on amyloid beta buildup as the main culprit in Alzheimer’s disease, but a new study suggests the real problem might lie in a stalled protein-cutting process in the ...

EMBO Press encourages applying due care in interpreting bibliometric measures such as CiteScore, h5-Index and Journal Impact Factor among others. EMBO is a foundation signatory of the San Francisco ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

In this manuscript the authors established a novel three-dimensional culture system for stratified epithelia that allows epithelial cells to undergo epithelial-to-mesenchymal transition (EMT) and ...

Arvinas Inc. (NASDAQ:ARVN), a biotechnology company specializing in protein degradation therapeutics, stands at a critical juncture as it approaches the release of pivotal clinical trial data.

Biochemistry is the study of the structure and function of biological molecules such as proteins, nucleic acids, carbohydrates and lipids. Biochemistry is also used to describe techniques suited ...

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report)’s share price reached a new 52-week low on Monday after Barclays lowered their price target on the stock from $48.00 to $32.00. Barclays currently has an ...

Herbicide development has slowed in recent years, but innovative research methods could soon drive significant progress in ...

After hours: February 4 at 4:20:01 PM EST Loading Chart for ARVN ...